Kargbo RB. Targeted Combination Therapies: A New Frontier in the Treatment of TP53 and KRAS Mutation-Associated Cancers.
ACS Med Chem Lett 2024;
15:15-16. [PMID:
38229755 PMCID:
PMC10788931 DOI:
10.1021/acsmedchemlett.3c00534]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2023] [Indexed: 01/18/2024] Open
Abstract
This Patent Highlight discusses novel therapeutic strategies for treating cancers associated with TP53 or KRAS mutations, particularly colorectal, pancreatic, and non-small-cell lung cancers. It focuses on the use of combination therapies involving two distinct compounds and a KRAS inhibitor. Researchers are exploring the effectiveness of these combined therapies in patient treatment and investigating their potential applications in drug manufacturing. With cancer being a global health challenge, these innovative strategies could present a breakthrough in enhancing survival rates and improving the quality of life for patients.
Collapse